About the Conference

The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.

Venue Information

The Union League of Philadelphia 140 South Broad Street Philadelphia, PA 19102 Tel: (215) 405-9578 www.unionleague.org/

Add to your Calendar

Sponsors

Sponsors_200px

Supporters

Supporters_200px

Who Should Attend

WhoShouldAttend

The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.

Industry News from BioCentury

  • Tracon raises $27M in B roundTracon Pharmaceuticals Inc. (San Diego, Calif.) raised $27 million in a series B round led by New Enterprise Associates. Additional new investors included BioMed Ventures and an undisclosed institutional investor. Existing investors JAFCO; Nextech Invest; Brookline Investments; Arcus Ventures; and BHP also participated.

    Tracon is developing TRC105, a human chimeric mAb against endoglin (CD105; ENG). The compound is in multiple oncology trials, including Phase II trials to treat renal cell carcinoma and glioblastoma and Phase I/II trials to treat metastatic breast cancer and soft tissue sarcoma.

    Paul Walker of New Enterprise Associates will join the Tracon board and Bruce Steel of BioMed Ventures will join as a board observer. Tracon also hired Patricia Bitar as CFO. Bitar was VP and corporate controller at NuVasive Inc. (NASDAQ:NUVA).
Read more

Industry News from PharmAsia

  • Regulation, Reimbursement Notes From TurkeyA PharmAsia News update shows Turkey working on support policies for domestic medical devices and pharmaceutical R&D, as well as more enforcement action related to fake cancer drugs.
Read more

Upcoming Supporter Events

Print

Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel
Philadelphia, PA

Read more